Resources
For the latest in immuno, sign up for our monthly newsletter to be among the first to receive exclusive insights,
in-depth market analyses, and expert articles directly to your inbox
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Unlocking%20the%20Future%20of%20Immune%20Cancer%20therapy%20Mock%20Up.png)
A concise report featuring insights from the prominent though leaders of Immuno 2024.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/R%26D%20Top%20Stories%20eBook%20Content%20Portal%20Image.png)
Top R&D Stories of 2023
Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/In-Convo-with-Eran-Ophir.png)
Drug Discovery & Development
Addressing Immunotherapy Resistance Through PVRIG And TIGIT Blockade
In this interview, Eran Ophir discusses Compugen's exciting approach to immune checkpoint inhibitors for the treatment of cancer and what makes them stand out from the crowd.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Vaccines-Event-Announcement-Industry-Spotlight-Featured-Image.jpg)
Vaccines
New Speakers Announced: Vaccines Europe Congress 2022
Exciting updates revealed about upcoming Vaccines Europe: In-Person congress happening 29-30 November 2022.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_480993123-scaled.jpg)
Drug Discovery & Development
Using Live Gut Bacteria as a Co-Therapy for Checkpoint Inhibitors
Microbiotica’s live bacterial therapeutic is currently manufacturing for phase Ib trials in 2023.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_384901223-scaled.jpg)
Drug Discovery & Development
Microbiome Solutions to Immuno-Oncology Problems
Investigating the role of the microbiota in checkpoint inhibitor response.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Monkey-Pox-Industry-Spotlight-Featured-Image.jpg)
Vaccines
US Doubles its Supply of Monkeypox Vaccines
The US government has more than doubled its supply of Monkeypox vaccines amidst rising fears.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_487145071-scaled.jpg)
Immuno-Oncology
Investigating the Core Tenet of Immunotherapy: MHC-I Peptide-Receptor Complexes
Axel Ducret, a Roche Senior Principal Scientist, takes us through his work on one of the most important cellular mechanisms in immunotherapy.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Vaccines-Interview-scaled.jpg)
Vaccines
Q & A with Derek O'Hagan
We interview Derek O'Hagan, Senior Advisor at GlaxoSmithKline Vaccines to learn more about the future of the vaccine.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Polio-Industry-Spotlight-Featured-Image.jpg)
Vaccines
Polio Resurgence Hits UK
The poliovirus is on the rise for the first time in nearly 40 years.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Conference-Announcements-Industry-Spotlight-Featured-Image.jpg)
Vaccines
Most Anticipated Presentations: Vaccines Europe
Discover key event highlights from Oxford Global's upcoming Vaccines Congress 2022.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/Discussion-Group-Cell-Therapies-Solid-Tumour-Therapy-Development.jpg)
Immuno-Oncology
The Future of CAR T for Solid Tumours: Antigen Discovery, Persistence, and Fitness
CAR T, the rockstar therapy of immuno-oncology, finds its next big challenge in translating research for use in solid tumours.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Immuno/AdobeStock_337178153-scaled.jpg)
Immuno-Oncology
Developing Novel Theranostic Approaches for the Development of Oncolytic Viruses
Single-cell, real-time analysis of oncolytic viruses’ efficacy, and replication in living cancer cells.
![](https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Vaccines-Industry-Spotlight-.jpg)
Vaccines
FDA Approves GSK’s MMR Vaccine
The FDA gives the green light to GSK’s measles, mumps, and rubella vaccine, providing US clinicians with a new treatment option for childhood inoculation for first time in more than 50 years.
Subscribe to Our Newsletter
Sign up for our monthly newsletter to
keep up with all things immuno